J. Mol. Biol. (2006) 356, 1222–1236
doi:10.1016/j.jmb.2005.11.095
Structural Basis for the Requirement of Two
Phosphotyrosine Residues in Signaling
Mediated by Syk Tyrosine Kinase
Teresa D. Groesch†, Fei Zhou†, Sampo Mattila
Robert L. Geahlen and Carol Beth Post*
Department of Medicinal
Chemistry and Molecular
Pharmacology, Purdue Cancer
Center and Markey Center for
Structural Biology, Purdue
University, West Lafayette
IN 47907, USA
The protein-tyrosine kinase Syk couples immune recognition receptors to
multiple signal transduction pathways, including the mobilization of
calcium and the activation of NFAT. The ability of Syk to regulate signaling
is influenced by its phosphorylation on tyrosine residues within the linker
B region. The phosphorylation of both Y342 and Y346 is necessary for
optimal signaling from the B cell receptor for antigen. The SH2 domains of
multiple signaling proteins share the ability to bind this doubly
phosphorylated site. The NMR structure of the C-terminal SH2 domain
of PLCg (PLCC) bound to a doubly phosphorylated Syk peptide reveals a
novel mode of phosphotyrosine recognition. PLCC undergoes extensive
conformational changes upon binding to form a second phosphotyrosinebinding pocket in which pY346 is largely desolvated and stabilized
through electrostatic interactions. The formation of the second binding
pocket is distinct from other modes of phosphotyrosine recognition in
SH2–protein association. The dependence of signaling on simultaneous
phosphorylation of these two tyrosine residues offers a new mechanism to
fine-tune the cellular response to external stimulation.
q 2006 Elsevier Ltd. All rights reserved.
*Corresponding author
Keywords: phosphotyrosine recognition; immune signaling; protein NMR;
isotope-filter NOESY; induced-fit binding
Introduction
The engagement of immune-recognition receptors
on hematopoietic cells activates multiple intracellular
signaling pathways in a manner dependent on the
recruitment of a Syk-family kinase to the ligated
receptor. In lymphocytes, recruitment to the antigen
receptor in B cells and T cells activates the proteintyrosine kinases, Syk and ZAP-70, respectively,
leading to their phosphorylation on multiple tyrosine
residues.1–5 Three of these sites are located within
linker B, the region that separates the tandem SH2
domains of the kinases from their catalytic domains. In
murineSyk,theseareY317,Y342,andY346.InZAP-70,
† T.D.G. & F.Z. contributed equally to this work.
Abbreviations used: PLCC, C-terminal SH2 domain of
PLCg; PDGF, platelet-derived growth factor; BCR, B cell
receptor; GST, glutathione-S-transferase; NOE, nuclear
Overhauser effect; CSP, chemical shift perturbation;
HSQC, heteronuclear single quantum coherence.
E-mail address of the corresponding author:
cbp@purdue.edu
the analogous sites are Y292, Y315 and Y319. Y317 in
Syk and Y292 in ZAP-70, when phosphorylated, serve
as inhibitory sites due to their interactions with
members of the Cbl family of adaptor proteins,
which are negative regulators of Syk family
kinases.6–8
Y342 and Y346 in Syk, and Y315 and Y319 in ZAP70, contribute in a positive manner to signaling such
that the phosphorylation of these residues enhances
the ability of each kinase to couple antigen receptors
to downstream signaling pathways. The elimination
of each individual tyrosine has both redundant and
unique effects on signaling and the presence of both
tyrosine residues is clearly required for optimal
activity.9–12 Many studies have identified effector
proteins with SH2 domains that bind within this
region. For example, PLCg-1 binds to a CD8-Syk
fusion protein via Y342 and/or Y346.13 The elimination of both inhibits the coupling of Syk to the
activation of PLCg-2 and mobilization of Ca2C in B
cells.12 Binding of the guanine nucleotide-exchange
factor, Vav1, requires Syk Y342 or Zap-70 Y315 and
elimination of this site inhibits signaling in mast cells
0022-2836/$ - see front matter q 2006 Elsevier Ltd. All rights reserved.
1223
Two Phosphotyrosine Requirement of Syk to Bind PLCg
and in reconstituted Syk-deficient B cells.14–16 Finally,
the replacement of Y319 in ZAP-70 inhibits the
binding of both Lck and PLCg-1 and blocks calcium
mobilization in T cells.17,18 Recent studies on the
regulation of Zap-70 suggest an alternative role for
these tyrosine residues analogous to that proposed
for Tyr604 and Tyr610 of the EphB2 receptor.19,20 The
phosphorylation of EphB2 Tyr604 and Tyr610 creates
docking sites for proteins with SH2 domains, and
relieves an inhibitory interaction between the juxtamembrane region of the receptor, containing these
two tyrosine residues, and the catalytic domain. For
Zap-70, the substitution of Tyr315 and Tyr319 with
residues other than Phe, or their complete elimination, enhances Zap-70-dependent signaling.19
In this study, we show that Syk Y342 and Y346
play primarily a positive rather than a negative role
in coupling the antigen receptor to the activation of
NFAT in B cells, and that both residues are required
for optimal signaling. In examining the mechanisms
by which the dual phosphorylation of this region
enhances signaling, we made the interesting
observation that SH2 domains from several proteins
actually recognize with high affinity a single site on
Syk that contains phosphotyrosine residues at both
positions 342 and 346. This result is in contrast to
the common SH2 recognition of a sequence with a
single phosphotyrosine residue. SH2 domains that
share a common fold of approximately 100 residues
form a central b-sheet with two flanking a-helices.
Typically SH2 domains bind a single pTyr residue
in a positively charged binding pocket on one side
of the central b-sheet with binding driven mainly by
the interaction between the pTyr and a conserved
arginine residue from the SH2 domain. While the
pTyr–pocket interaction contributes most of the
binding energy,21 SH2 domains confer specificity by
contacts that take place between side-chains
C-terminal to the pTyr. The determination of the
optimal binding sequence of many SH2 domains
from studies on peptide libraries22 led to the
classification of SH2 domains into four groups
determined by a single residue on the peptidebinding edge of the central b-sheet (residue bD5),
which correlated with the binding specificity of the
SH2 domains for the residues C-terminal to
phosphotyrosine. A few exceptions to these rules
have been identified but, on the whole, most of
the SH2 domain interactions previously detected
have followed this classification.23 Both Y342 and
Y346 of Syk individually are predicted to bind with
high affinity to group I (e.g. Lck) and group II (e.g.
Vav) SH2 domains, while the PLCg C-terminal
SH2 domain, a group III domain, is not predicted to
bind either sequence with high affinity. However,
we found that all three of these SH2 domains can
bind with high affinity to this site when it is
phosphorylated on both Y342 and Y346.
To establish the structural basis for SH2 recognition of a doubly phosphorylated ligand, we
determined the NMR structure of the complex
between the C-terminal SH2 domain of PLCg
(PLCC) and a doubly phosphorylated peptide
derived from the Syk linker B region surrounding
Y342 and Y346. A comparison of this structure with
the previously solved structure of PLCC bound to a
singly phosphorylated peptide from the plateletderived growth factor (PDGF) receptor24 reveals
that PLCC undergoes large conformational changes
upon binding the doubly phosphorylated peptide.
Interestingly, these changes in conformation create
a second phosphotyrosine-binding pocket to
accommodate pY346 of Syk and provide electrostatic stabilization of the phosphoryl group. The
formation of the secondary binding pocket is
distinct from previously described modes of
phosphotyrosine recognition. Residues important
for the formation of the second pTyr binding pocket
are conserved within the SH2 domains of proteins
that share the ability to bind the doubly phosphorylated site on Syk linker B, but are missing from
many other SH2 domains, suggesting that the
stoichiometry of phosphorylation within this region
may be used to modulate the nature of Syk–protein
interactions.
Results and Discussion
Importance of Syk Y342 and Y346 for signaling
In B cells, Syk couples the B cell receptor (BCR) to
the mobilization of calcium and the activation of
the transcription factor, NFAT. To examine the
contributions of the linker B tyrosine residues to
Syk’s ability to activate NFAT, we transfected
Syk-deficient DT40 B cells with plasmids directing
the expression of Syk or one of several Syk mutants
along with a luciferase reporter plasmid driven by
NFAT. The level of luciferase activity induced
following receptor cross-linking is shown in
Figure 1. The substitution of Y317 for phenylalanine
enhanced the ability of wild-type Syk to signal. This
was expected, as the role of Y317 as an inhibitory
site of phosphorylation has been reported.12 In the
EphB2 receptor, the juxtamembrane region, which
includes Y604 and Y610, makes extensive contacts
with the N-terminal lobe of the catalytic domain
to inhibit its activity.20 A similar mechanism has
been proposed for the regions of Zap-70 and Syk
that surround Y315 and Y319 or Y342 and Y346,
respectively.19 To determine if the region encompassing Y342 and Y346 in Syk was inhibitory to the
BCR-stimulated activation of NFAT, we deleted 20
amino acid residues from this area to generate
Syk(D335–354) (SykD) and expressed this mutant in
Syk-deficient DT40 cells. SykD exhibited a considerably reduced ability to couple the BCR to the
activation of NFAT as compared to wild-type Syk
(Figure 1(a)) even though it was expressed at
comparable levels (Figure 1(b)). Thus, for the
activation of NFAT in B cells, the major role for
this region of linker B is to support rather than
suppress signaling.
The contributions of Y342 and Y346 to signaling
in B cells are most readily visualized in the context
1224
Two Phosphotyrosine Requirement of Syk to Bind PLCg
0.6
of the Syk(Y317F) mutation, which eliminates the
negative regulatory site and enhances Syk’s ability
to couple the BCR to the mobilization of Ca2C and
activation of NFAT. These responses are attenuated
by the removal of both Y342 and Y346.12 However,
the contributions of each individual tyrosine have
not been measured. To examine this, we prepared
constructs for the expression of Syk(Y317F),
Syk(Y317F/Y342F),
Syk(Y317F/Y346F)
and
Syk(Y317F/Y342F/Y346F) and transfected these
into Syk-deficient DT40 B cells. The elimination of
either Y342 or Y346 alone reduced the BCRstimulated activation of NFAT (Figure 1(c)). The
elimination of both residues further compromised
signaling. This reduced signaling was not a
consequence of lower levels of expressed protein,
since comparable amounts of Syk could be detected
in each set of transfected cells (Figure 1(d)). We
conclude that Syk couples the BCR to the activation
of NFAT most efficiently when both Y342 and Y346
are present. The presence of both tyrosine residues
is required for optimal signaling in mast cells.11
0.4
Syk interactions with SH2 domains
3
2.5
2
1.5
1
Y317F
0
Syk ∆
0.5
Syk
Relative Luciferase Activity
(a)
1.2
1
0.8
Y317F/Y342F/Y346F
Y317F/Y346F
Syk-
0
Y317F/Y342F
0.2
Y317F
Relative Luciferase Activity
(c)
Y317F
Syk
Syk ∆
(b)
Y317F/Y342F/Y346F
Y317F/Y342F
Y317F/Y346F
Y317F
(d)
Figure 1. Effect of the replacement or elimination of
linker region tyrosine residues on the Syk-dependent
activation of NFAT. (a) NFAT activity in anti-IgMtreated, Syk-deficient DT40 cells transiently transfected
with an NFAT-driven luciferase reporter construct and a
plasmid coding for wild-type murine Syk (Syk), Syk
with Y317 replaced with phenylalanine (Y317F) or Syk
with residues 335–354 deleted from linker B (SykD). The
values are compared to those obtained from cells
transfected with Syk, which is normalized to a value
of 1.0. (b) The relative levels of Syk expressed in the
transfected cells from one trial shown in (a). (c) NFAT
activity in anti-IgM-treated, Syk-deficient DT40 cells
transiently transfected with an NFAT-driven luciferase
reporter construct and an empty vector (SykK) or a
plasmid encoding the indicated Syk mutant. Values
were normalized to those of cells transfected with
Syk(Y317F). (d) The relative levels of Syk expressed in
transfected cells from one representative experiment
shown in (c).
To gain an understanding of how Y342 and Y346
combine to enhance signaling, we examined
the mechanisms by which proteins reported to
interact in this region are able to bind to Syk. We
first examined the binding of phosphopeptides
generated from a tryptic digest of in vitro autophosphorylated Syk to immobilized glutathioneS-transferase (GST)-SH2 domain fusion proteins
derived from PLCg-1 (Figure 2(a) and (b)), the first
protein reported to bind to Syk in this region.13
Phosphopeptides retained by the GST-SH2 domains
were compared to the total digest. A single
phosphopeptide was the predominant species that
bound to fusion proteins containing either the
C-terminal SH2 domain or both the C and
N-terminal SH2 domains of PLCg-1 (Figure 2(a)).
This peptide, identified as EALPMDTEVpYESPpYADPEEIRPK, contains phosphotyrosine residues
at both positions 342 and 346.3 The interaction
between Syk-derived phosphopeptides and PLCg-1
was specific for PLCC as no phosphopeptide was
observed to bind to the N-terminal SH2 domain.
Importantly, phosphopeptides containing only a
single phosphate group on either Y342 or Y346,
which migrate slightly higher on the alkaline gel
than the doubly phosphorylated peptide, failed to
bind to PLCC with sufficient affinity to be detected
under these conditions. These results indicate that
the phosphorylation of both Y342 and Y346 is
important for the interaction of Syk with PLCC.
This idea is further supported by binding studies on
phosphopeptides derived from mutated Syk. No
phosphopeptide bound to PLCC when it was
generated from forms of Syk that contained a single
point mutation at either Y342 or Y346 (Figure 2(b)).
Signaling in B cells is mediated mainly by the
PLCg-2 isoform,25 whose C-terminal SH2 domain
shares 65% sequence identity with and 81%
1225
Two Phosphotyrosine Requirement of Syk to Bind PLCg
blotting analyses of eluted proteins with antibodies
against PLCg-2 indicated that the protein bound
preferentially to the doubly phosphorylated
peptide (Figure 3(a)), indicating that the interaction
of PLCC is similar for both isoforms of PLCg.
(a)
Phospho-Y317
MonophosphoY342/Y346
(a)
PLCg2
BisphosphoY342/Y346
Vav1
p85
(C) (N) (N+C)
Total
Digest
SHP1
Lck
PLCγSH2
pYpY
YpY
pYY
YY
Lysate
Bound Peptide
Total Digest
Bound Peptide
Total Digest
(b)
Phospho
Y317
F346
Figure 2. Binding of PLCC to phosphopeptides derived
from Syk linker B. (a) The C-terminal SH2 domain of
PLCg-1 binds a Syk-derived phosphopeptide. Tryptic
phosphopeptides generated from autophosphorylated
Syk were applied to immobilized GST-fusion proteins
that contained the C-terminal (C), N-terminal (N), or both
(NCC) SH2 domains of PLCg-1. The migration positions
of the three peptides containing the linker region tyrosine
residues are indicated. Y342 and Y346 lie within the same
phosphopeptide, which exists in forms containing either
one or two phosphotyrosine residues. (b) Phosphorylation of both Y342 and Y346 are required for high-affinity
binding. Tryptic phosphopeptides were generated from
in vitro autophosphorylated Syk, Syk(Y342F), or
Syk(Y346F) and adsorbed to the immobilized GST-Cterminal SH2 domain of PLCg-1. Bound phosphopeptides were separated by alkaline PAGE and compared to
the total digest.
sequence similarity to that of PLCg-1. To determine
if PLCg-2 shares the same preference for binding a
doubly phosphorylated peptide as PLCg-1, we
prepared solid supports containing immobilized
peptides corresponding in sequence to Syk amino
acid residues 338–353 and containing either no
phosphate group, a single phosphate group at Y342,
a single phosphate group at Y346 or phosphate
groups at both positions. Each resin was incubated
with lysates prepared from DG75 human B cells,
washed extensively and then treated with buffer
containing SDS to elute bound proteins. Western
WT
WT
Y346F
F342
Y342F
WT
Y290F
Monophospho
Y342/Y346
Bisphospho
Y342/Y346
LckSH2
Monophospho
Y342/Y346
Bisphospho
Y342/Y346
Total digest
Phospho
Y317
Bound Peptide
(b)
Total Digest
Grb2
(c)
SH2 domains: Lck Abl Shc p85C
SH2 domains: Vav
PLCg
Bisphospho
Y342/Y346
N N+C C
Figure 3. Binding of multiple SH2 domains to
phosphopeptides derived from Syk linker B. (a) Binding
of proteins to immobilized phosphopeptides. Lysates
from DG75 B cells were adsorbed to resins containing
immobilized peptides corresponding to residues 338–353
of Syk and containing either no phosphate group (YY), a
phosphate group at Y342 (pYY), a phosphate group at
Y346 (YpY) or phosphate groups at both positions (pYpY).
Bound proteins were analyzed by Western blotting for the
presence of PLC-g2, Vav1, p85, SHP1 or Grb2. Lysates
from Jurkat T cells were analyzed for the binding of Lck.
(b) The Lck SH2 domain also binds to a doubly
phosphorylated peptide. Tryptic phosphopeptides generated from autophosphorylated Syk, Syk(Y290F),
Syk(Y342F) or Syk(Y346F) were adsorbed to the immobilized SH2 domain from Lck and analyzed as described in
the legend to Figure 2. (c) Binding of the Syk phosphopeptide by multiple SH2 domains. Tryptic phosphopeptides generated from autophosphorylated Syk were
adsorbed to immobilized SH2 domains from Lck, Abl,
Shc, p85 (C-terminal domain), Vav1, or PLCg-1. Bound
peptides were eluted and analyzed as described in the
legend to Figure 2.
1226
Proteins bound to the immobilized peptide resins
also were analyzed by Western blotting to detect
other reported binding-partners of Syk in order to
determine if any of these shared the same binding
specificity. Vav1, which has been reported to require
Y342 for its interactions with Syk,14 bound to the
peptide containing pY342, but not to the peptide
containing pY346. Interestingly, Vav1 bound most
strongly to the doubly phosphorylated peptide.
This is consistent with the requirement for Y342 or
both Y342 and Y346 for the robust phosphorylation
of Vav1 in primary mast cells.11 The p85 subunit of
PI3K also bound selectively to the doubly phosphorylated peptide, while SHP1 did not bind to any
of the peptides. Since the region surrounding Y342
and Y346 is conserved in ZAP-70, and Lck has been
reported to bind in this region, we used these resins
to recover proteins from lysates of Jurkat T cells. Lck
bound to all three phosphopeptides, but also
exhibited a preference for the doubly phosphorylated peptide. Thus, multiple SH2 domains share
the ability to recognize a single site on Syk
containing two phosphotyrosine residues. However, not all proteins with SH2 domains preferred
binding sites with two phosphotyrosine residues.
Grb2, for example, bound preferentially to the
singly phosphorylated peptide containing pY346.
Thus, Grb2 binds preferentially to this region when
it contains one phosphotyrosine residue, but this
binding is reduced when the second tyrosine
residue is phosphorylated. It is interesting to note
that the activation of Erk in primary mast cells is
particularly sensitive to the presence of Y346.11
To explore further the nature of SH2 domains that
bound preferentially to the doubly phosphorylated
peptide, we used a total of seven GST-SH2 domain
fusion proteins in phosphopeptide pull-down
experiments using the assay described in Figure 2.
Of these seven, three (Lck, Vav and PLCC) bound
the doubly phosphorylated Y342CY346 fragment
preferentially (Figure 3(c)). In addition, the Fgr SH2
domain has been shown to select the same doubly
phosphorylated peptide.26 The remaining four SH2
domains (Shc, Abl, the N-terminal SH2 domain of
PLCg, and p85C, the C-terminal SH2 domain of the
p85 regulatory subunit of phosphoinositide
3-kinase) did not bind to Syk at this site. The
binding of p85 to the immobilized phosphopeptide
described in Figure 3(a) is most likely a function
of the N-terminal SH2 domain, as p85C
binds selectively to Syk at pY317 and p85N binds
elsewhere in linker B.27
A more complete analysis of phosphopeptide
binding by the SH2 domain of Lck showed results
similar to those observed for PLCC. The immobilized SH2 domain from Lck retained only the
doubly phosphorylated peptide containing pY342
and pY346 (Figure 3(b)). The singly phosphorylated
peptides did not bind with sufficiently high affinity
to the Lck SH2 domain to be visualized in this assay
where the phosphopeptides are present at very low
concentrations. Furthermore, no tryptic phosphopeptides derived from either of two mutant forms
Two Phosphotyrosine Requirement of Syk to Bind PLCg
of Syk containing phenylalanine substituted for
Y342 or Y346 bound to the immobilized Lck SH2
domain. Substitution of an irrelevant tyrosine
residue, Y290, for phenylalanine had no effect on
the binding of the doubly phosphorylated peptide.
These data indicate that the Lck SH2 domain, like
PLCC, also binds preferentially to the doubly
phosphorylated peptide. By analogy, it is likely
that the phosphorylation of ZAP-70 on both Y315
and Y319 would provide a higher affinity interaction with Lck than would the phosphorylation of
either site alone.
NMR structure of the Syk–PLCg complex
To determine how a single SH2 domain could
accommodate a phosphopeptide containing two
phosphotyrosine residues, we solved the NMR
structure of PLCC bound to DTEVpYESPpYADPE
(designated pYpY) using uniformly 15N/13Clabeled PLCC and unlabeled pYpY (see Experimental Procedures). PLCC was chosen for analysis,
since an NMR structure of the SH2 domain bound
to a singly phosphorylated peptide is available for
comparative purposes.24 Statistics for the final
structures are given in Table 1.
Because of extensive chemical shift overlap in
pYpY resonances, many intermolecular NOE peaks
could not be assigned uniquely in the initial stage of
structure calculations. A rough orientation of the
peptide by initial docking with the unique intermolecular NOE assignments allowed for the assignment of additional intermolecular NOE peaks to
give 29 intermolecular NOE restraints. Residues
Table 1. Structural statistics of 15 final structures
Restraints
Protein NOE
Intra
Sequential
Mediuma
Long-rangeb
Ambiguous
Total
Intermolecular NOE
Torsion angle
phi angles
psi angles
Hydrogen bond
Average pairwise RMSD of
ensemble
Complexc (Å)
SH2 domain residues 10–97 (Å)
Peptide residues 1–13 (Å)
Peptide residues 3–11 (Å)
Ramachandran plot
Most favored region (%)
Additionally allowed region (%)
Generously allowed region (%)
Disallowed region (%)
290
254
123
204
462
1333
29
55
55
26
Backbone
2.09G0.3
1.16G0.2
3.11G0.7
1.76G0.5
All
2.6G0.2
2.74G0.3
3.66G0.5
63.7
27.5
5.9
2.9
a
Medium-range NOEs are defined as two to three residues
apart.
b
Long-range NOEs are defined as four or more residues
apart.
c
PLCC residues 1–105 and pYpY residues 1–13.
Two Phosphotyrosine Requirement of Syk to Bind PLCg
P345 and pY346 have five and nine interactions,
respectively. Residues pY342 and E350 have four
NOE interactions each, residue E340 has two NOE
interactions, and residues T339, E343 and P349 have
a single NOE interaction. Residues D338, T339,
V341, S344, A347, and D348 have no NOE
interaction with the protein. While some sidechains do not contact PLCC and are without NOE
interactions, the restrained regions of the peptide
are spread throughout the molecule so that the
overall structure is well defined.
A superposition with respect to the central
b-sheet of the final 15 structures is shown in
Figure 4(a). The average structure of the PLCC–
pYpY complex was calculated from the 15 final
structures and is shown in Figure 4(b). The pYpY
1227
peptide binds across the edge of the b-sheet in an
extended conformation with residue pY342 in the
primary pTyr binding pocket. The peptide backbone continues from the primary pTyr pocket along
the top of the EF loop and toward the BG loop.
Overall, 2028 Å2 are buried upon pYpY binding to
the SH2 domain.
The negative phosphate group of pY342 interacts with R37 of PLCC, which corresponds to the
ArgbB5 residue that is conserved throughout
the SH2 domain family (Figure 5(a)). The ring of
the tyrosine residue also makes contacts with R39,
A46, H57, and C58 (Figure 5(a)). Additional
electrostatic contacts are seen between the
N-terminal half of pYpY (residues E340 and
E343) and PLCC (residues R18, R39, and R59),
but interactions with the C-terminal half of the
peptide are mainly hydrophobic in nature with
the exception of pY346 (Figure 5(b)).
The interaction between PLCC and the second
pTyr of the peptide (pY346) occurs on the opposite
side of the central b-sheet from the primary
pTyr-binding site (Figure 5(c)). A second phosphotyrosine pocket is formed, which distinguishes
recognition of Syk linker B from other SH2–protein
associations. Two lysine residues, K54 and K56,
interact with the phosphate group and close over
pY346 to form the second pTyr pocket. The pocket
buries 576 Å2 of the pTyr surface, which is more
than is buried in the primary pTyr pocket (488 Å2).
The formation of the pocket results in large
conformational changes in PLCC upon binding
pYpY (described below).
Comparison of the pYpY-PLCC and pY1021PLCC SH2 complexes
Figure 4. Structure of the PLCC-pYpY complex. (a)
Overlay of the final 15 structures of the PLCC-pYpY
complex (residues 10–97). The structures were aligned by
the central b-sheet of PLCC. The protein is shown in grey
and the peptide is shown in cyan. (b) The energyminimized average structure of the PLCC–pYpY complex.
The protein is shown in grey, and the peptide is shown in
cyan with the pTyr residues highlighted in red.
The structure of PLCC has been determined in
complex with a singly phosphorylated peptide
derived from the PDGF receptor designated
pY1021 (DNDpYIIPLPDPK).24 pY1021 has the
optimal binding sequence for PLCC (pY-V/I-I/
L-P) as defined by Songyang et al.22 Since PLCC
is classified as a group III SH2 domain, it is
expected to bind peptides with a hydrophobic
residue at the pTyr C1 position. In contrast, the
pYpY peptide has an acidic residue following
pY342, contains a large fraction of charged and
polar residues, and is not predicted to bind to a
group III SH2 domain. Unlike the pYpY complex,
most of the side-chain interactions between
pY1021 and PLCC are hydrophobic in nature,
with the exception of the pTyr residue.
The peptides in the two complexes differ in
their binding position as shown in Figure 6(a).
The root-mean-square difference (RMSD) in the
peptide Ca coordinates is 8.8 Å, a value significantly larger than reasonably expected from
experimental uncertainty. The orientation of
pYpY in the vicinity of the primary pTyr pocket
is defined by intermolecular nuclear Overhauser
effect (NOE) interactions of the pY342 side-chain
(red, Figure 6(a)) with A46, C58, S44, and R39 of
1228
Two Phosphotyrosine Requirement of Syk to Bind PLCg
Two Phosphotyrosine Requirement of Syk to Bind PLCg
1229
Figure 6. Comparison of the pYpY- and pY1021-PLCC complexes. (a) Stereoview of the overlay of pYpY (cyan, red)
and pY1021 (yellow, pink). The structures were aligned on the basis of the central b-sheet of the proteins. The RMSD of
the two peptides is 8.8 Å. (b) Stereoview of Arg residues from the primary pTyr binding site in the pYpY complex (cyan,
red) and the pY1021 complex (yellow, pink).
PLCC, as well as side-chain NOE interactions of
nearby residues E340 (with R39 and N40) and
E342 (with E41). Together, these contacts position
pY342 deeper in the pocket than the phosphotyrosine residue of pY1021, and result in the
N-terminal end of helix aA being correspondingly displaced (described below). This position
of the pTyr in the primary pocket affects the
interactions of pTyr with the positively charged
SH2
residues
surrounding
the
pocket
(Figure 6(b)). In both complexes, pTyr interacts
with the conserved R37, but in the pY1021
complex, pTyr also contacts three other surrounding arginine residues: R18, R39, and R59. In the
pYpY complex (cyan and red, Figure 6(b)), the
position of R18 is altered by the movement of aA
and consequently is too far away to interact
strongly with pY342. Residues R39 and R59 are
closely overlapped in the two structures but,
since pTyr in the pYpY complex binds further
into the pocket, the interaction with these
charged residues appears less favorable. Instead
of contacting pY342, these three arginine residues
contribute other electrostatic interactions with
pYpY (Figure 5(b)) that are not possible for
pY1021 because of the hydrophobic pTyrC1
residue.
Conformational changes induced by the binding
of pYpY
Figure 7(a) is an overlay of the Ca trace of PLCC in
complex with either pYpY (grey) or pY1021 (gold)
where the structures were aligned by the central
b-sheet. The Ca RMSD between the two structures is
5.0 Å for residues 10–97. The central b-sheet of the
two proteins has a Ca RMSD of 1.6 Å over 25
residues, and is similar, except that in the complex
with pYpY there is a bulge in the bD strand such that
residues K56 to C58 do not possess ideal main-chain
geometry for a b-strand nor form hydrogen bonds
with strand bC.
The largest difference between the pYpY and
pY1021 complexes occurs in the BG loop. In the
Figure 5. (a) Interactions within the primary pTyr binding pocket. pY342 is shown in red and important residues from
the protein are shown in green. Positively charged residues from the protein are shown in blue. (b) Electrostatic
interactions between the N-terminal half of pYpY and PLCC. The negatively charged residues from the peptide are
shown in red, and the positively charged residues are shown in blue. (c) Stereoview of interactions within the secondary
binding site of the PLCC-pYpY complex. pY346 is shown in red, and important residues from the protein are shown in
green. The two lysine residues that interact with pY346 (K54 and K56) are shown in blue.
1230
structure of PLCC bound to pY1021, this loop
interacts with residues from the central b-sheet and
with the pTyr C1 to C3 residues of the pY1021
peptide. In the pYpY complex, the center of the BG
loop moves outward by approximately 11 Å relative
to its position in the pY1021 complex to expose a
new surface for binding the secondary pTyr
residue. Another large difference between the two
Two Phosphotyrosine Requirement of Syk to Bind PLCg
structures is seen near the primary pTyr binding
pocket: the orientation of aA differs in the two
complexes due to the position of pY342 from pYpY
in the primary pocket. There is a change in both the
angle of the helix axis relative to the b-sheet as well
as a 208 rotation about the helix axis. All of the large
conformational differences are supported by
measured NOE restraints. For example, the open
Figure 7. The binding of pYpY induces changes of conformation in PLCC. (a) Stereoview of the comparison of PLCC
bound to either the singly phosphorylated pYpY (grey) or pY1021 (yellow) and aligned on the basis of the central b-sheet of
the protein. Large changes exist for aA, aB, bD, the BG loop, and the secondary b-sheet. (b) Surface representation of PLCC
bound to pYpY. The electrostatic potential of the proteins calculated with the program GRASP is mapped on the surface of
the protein. (c) Surface representation of PLCC bound to pY1021. The two structures in (b) and (c) were aligned, and any
differences between the two surfaces arise from differences in the protein conformation not protein orientation.
Two Phosphotyrosine Requirement of Syk to Bind PLCg
conformation of the BG loop is defined by NOE
interactions such as Y90 (BG loop) with both A51
(bC) and E52 (CD loop), as well as interactions
between K92 (BG loop) and G32 (bB). The
orientation of aA is also well determined by
numerous NOE interactions, including E14 and
S15 with K38 (bB), L16 with R37 (bB), and M26 (aA)
with S48 (bC).
Interestingly, the changes in the conformation of
PLCC generate different surface topologies with
distinctive electrostatic potentials. The electrostatic
potential calculated with the GRASP program is
mapped to the solvent-accessible surface of the
pYpY complex in Figure 7(b) and the pY1021
complex in Figure 7(c). The change in the surface
and electrostatic signature is obvious. Most striking
is the formation of the second pTyr binding site by
K54 and K56 closing over pY346 to bury the ring
and hide it from view as seen in Figure 7(b). In the
pY1021 complex, these two residues are highly
solvated to give a more electropositive surface to
the SH2 domain. Differences are evident also near
the BG loop (top left in Figure 7(b) and (c)). In the
pY1021 complex, the BG loop forms the upper wall
of the hydrophobic binding cleft. In the pYpY
complex, displacement of the BG loop exposes the
hydrophobic residues (Y49, Y84, A51, I47) that were
buried. The bulge in the central b-sheet of the pYpY
complex is evident as well. In the pYpY complex,
the bulge in bD forms a prominent ridge that
increases surface contact with the pTyrC1 residue.
Without the bulge, pY1021 binds along a continuous, flat surface in a hydrophobic binding cleft that
extends from the pTyr pocket.
We compared the nine SH2 domains with
coordinates deposited in the PDB for free and
bound states or complexes with multiple ligands.
The SH2 domains of Lck28,29, Src33, APS30, Grb232,
and NSyp31 show essentially no conformational
change upon peptide binding. Four of the SH2
domains (SAP/SH2D1A, p85C, and p85N) undergo
relatively small conformational changes upon
binding. Phosphopeptide binding to the SH2
domain of either SAP/SH2D1A34 or p85C35,36
causes up to a 1.3 Å displacement localized to the
backbone C-terminal half of the SH2 or the
secondary b-sheet, respectively. The changes are
considerably smaller than those observed for PLCC.
The NMR structure of p85N in the presence of a
doubly phosphorylated peptide derived from the
polyoma middle T antigen shows several differences relative to the unbound conformation;37
however, it must be pointed out that alternative
structures deposited in the PDB for unligated p85N
SH2 domain have similarly large conformational
discrepancies. Thus, the extent to which the
conformational differences are the result of ligand
binding is unclear.
The only previous case of an SH2 domain
observed to undergo a large loop reorientation as
a result of binding is Itk. The conformation change
in Itk SH2 stems from isomerization of a proline
residue within the CD loop that rearranges the loop
1231
and allows binding of its own SH3 domain distant
from the pTyr binding pocket.38 This conformational change is therefore not associated with protein–
protein recognition of phosphotyrosine, in contrast
to the induced-fit observed for PLCC.
Effect of pY346 and the second phosphotyrosinebinding pocket on PLCC–phosphopeptide
interactions
Structural analyses indicate that PLCC binds
pY342 in the canonical phosphotyrosine-binding
site and undergoes a conformational change to
accommodate pY346 in a second, previously
undescribed binding pocket. To analyze the contributions of this second binding site to the phosphopeptide–SH2 domain interaction, we compared
the chemical shift perturbations (CSP) in the
15
N-heteronuclear single quantum coherence
(HSQC) spectrum of PLCC upon binding pYpY or
the singly phosphorylated, Syk-derived peptide
DTEVpYESPYADPE (designated pYY). CSP is the
result of a change in the 15N environment upon
binding of a ligand from either a direct interaction
with the ligand or from conformational changes
within the protein. The structure of PLCC in
complex with pYY could not be determined because
of a lack of observable intermolecular interactions
by isotope-filtered NOE spectroscopy (NOESY).
The difference in the CSP between pYpY and the
singly phosphorylated peptide shown in Figure 8(a)
was used to determine the variations in how the
two peptides bound to PLCC.
Negligible differences in CSP for residues in the
primary pTyr pocket suggest that pYY binds
similarly to pYpY in the N-terminal part of the
peptide with pY342 in the canonical pocket. The
electrostatic interactions between E340 and E343
would still be present and cause pY342 to insert
further into the pocket, as seen with the pYpY
structure. Larger differences were seen in the
N-terminal half of bD where K54 interacts with
pY346 in pYpY, as well as in the BG loop of
the protein (Figure 8(b)). One large disparity is the
perturbation of L89 in the BG loop. This residue is
solvent-exposed in the PLCC complex with pYpY,
but in the structure with pY1021, the BG loop is
closed, and L89 contacts the bound peptide. The
changes seen in the residues that interact with the
C-terminal half of the peptide suggest that the BG
loop is more like the pY1021 structure where the BG
loop is closed and L89 interacts with the peptide.
To determine how the formation of this second
binding pocket influences the affinity of the
interaction between PLCC and the Syk-derived
peptide, we assessed the binding affinities of PLCC
for both pYpY and pYY. The rates and the binding
constants determined from surface plasmon resonance analysis are given in Table 1. Good agreement
between the kinetic rate constants and the equilibrium constants for both peptides indicates the
reliability of the kinetic rates. pYpY binds to PLCC
with a dissociation constant of approximately
1232
Two Phosphotyrosine Requirement of Syk to Bind PLCg
Figure 8. CSP differences between the PLCC-pYpY and -pYY complexes. (a) Differences in CSP for PLCC binding
pYpY and pYY plotted as a function of PLCC residue number. (b) CSP differences between pYpY and pYY greater than
0.04 mapped onto the structure of PLCC (colored orange).
70 nM, while pYY has an approximately sevenfold
decrease in the binding affinity (KDZ500 nM) as a
result of a slower on-rate. This decrease is
apparently sufficient to prevent detection at the
lower concentration levels of Figure 2(b). A change
in the on-rate of an interaction may be rationalized
by removal of an electrostatic interaction between
the peptide and the protein. Electrostatic interactions orient the protein and its ligand, and
thereby facilitate correct positioning of the ligand
for binding and enhance the on-rate of the complex.
All of the SH2 domains shown to bind to the
doubly phosphorylated region of Syk contain a
lysine residue at position K56, while only PLCC has
a second lysine residue, K54. This suggests an
important interaction between K56 and pYpY. To
test the contribution of K56 to the binding of pYpY,
the residue was mutated to glutamine based on the
corresponding residue in the N-terminal SH2
domain of PLCC that does not bind to Syk.
Mutation of K56 to glutamine caused an approximate sevenfold reduction in the affinity of the PLCC
for pYpY as a result of an increase in the off-rate of
the interaction (Table 2), consistent with K56
contributing to the stabilization of PLCC-pYpY
through electrostatic interaction with pY346. The
presence of lysine at K56 likely accounts for the
interactions of Lck, Fgr, Vav1 and the N-terminal
Table 2. Binding constants of PLCC measured by SPR
6
K1
K1 a
ka (10 M s )
kd (sK1)a
KA (106 MK1)b
KD (mM)c
a
PLCC-pYpY
PLCC-pYY
K56Q-pYpY
1.8 (G0.025)
0.12 (G2.1!10K3)
15.0
0.066/0.070 (G0.009)
0.27 (G0.01)
0.13 (G1.1!10K3)
2.0
0.49/0.4 (G0.1)
2.7 (G0.14)
1.2 (G0.06)
2.2
0.46/0.47 (G0.13)
Values for ka and kd are estimated from the time-dependent SPR binding curves.
KAZka/kd.
c
First KD value determined from rate constants, ka and kd. Second KD value estimated from the steady-state values of the SPR binding
curves.
b
1233
Two Phosphotyrosine Requirement of Syk to Bind PLCg
SH2 domain of p85 with the doubly phosphorylated Syk peptide. The Abl SH2 domain, the
N-terminal SH2 domain of PLCg, the Grb2 SH2
domain and the SHP1 SH2 domain all lack this
residue and do not bind well to the doubly
phosphorylated peptide. The one outlier we have
identified so far is the C-terminal SH2 domain of
p85, which has lysine in the equivalent position of
K56, but does not bind the doubly phosphorylated
Syk linker B, suggesting that other structural
features can influence the phosphopeptide-SH2
domain interaction.
Conclusions
Following aggregation of the BCR, Syk is
phosphorylated on multiple tyrosine residues,
including a pair of closely spaced residues within
the linker B region, Y342 and Y346. Analyses of
BCR-dependent signaling in reconstituted DT40
cells indicate that phosphorylation of both residues
is important for optimal signaling by a mechanism
that cannot be accounted for by a release of
inhibition of the catalytic domain. That Syk is
phosphorylated simultaneously on both Y342 and
Y346 in B cells has been documented by both
metabolic labeling3 and mass spectrometric
analyses.39 Binding studies indicate that the importance of both residues is reflected in an enhanced
affinity for a subset of proteins containing SH2
domains that are able to recognize binding sites
containing two phosphotyrosine residues. Examination of the structure of a doubly phosphorylated
peptide bound to the C-terminal SH2 domain of
PLCg-1 indicates that each phosphotyrosine residue makes critical contributions required for a highaffinity, specific interaction.
There is considerable interest in determining how
different factors influence the propagation of
signals through phosphotyrosine signaling cascades. In most current models, regulation is based
on the phosphorylation and interaction of one pTyr
residue with a single SH2 domain. Nevertheless,
there are now four structures of single SH2 domains
interacting with sites containing two phosphotyrosine residues. In addition to PLCC, these include
SH2 domains from p85,37 Src40 and the adaptor
protein APS,30 but in contrast to the PLCC
complexes, none of these interactions shows substantial differences in SH2 conformation. In the case
of the two phosphotyrosine residues on Syk, we
find that SH2 domains from multiple binding
partners (PLCg, Vav, p85N Fgr and Lck) recognize
the doubly phosphorylated site, and both phosphotyrosine residues affect signaling in cells, as well as
binding affinity. Control of the relative phosphorylation of the pY342 and pY346 sites could fine-tune
the response of the cell to external stimulation
through the B-cell receptor by determining
relative binding affinity of the specific SH2
domain-containing proteins that can interact with
Syk. The B cell signaling studies demonstrate that
the alternative phosphorylation states do indeed
alter the amount of signal that is propagated within
the cell. Syk containing only pY342 or only pY346
might signal in cells by binding to a subset of
effectors that recognize each individual docking
site via a classical SH2 domain–phosphopeptide
interaction. The phosphorylation of the second
tyrosine residue can then allow for further control
either by enhancing the affinity of the interaction to
increase the quantity of signaling or by allowing the
binding of an SH2 domain with a different
specificity to affect the quality of signaling. It is
intriguing to also speculate that certain SH2
domains that do not contain a positively charged
residue corresponding to K56 at the bD3 position
can bind preferentially to the singly phosphorylated
peptide over the doubly phosphorylated peptide
to allow for negative regulation of SH2 binding
by phosphorylation. In fact, Grb2 is a potential
candidate for this type of protein. Such a mechanism could account for the differential coupling of
singly phosphorylated forms of Syk to different
downstream signaling pathways as has been
observed in primary mast cells.11 The solution
structure of PLCC-pYpY shows that recognition of
the second phosphotyrosine residue induces a
substantial conformational change in the SH2
domain to form a second pTyr pocket that may be
a common feature for recognition of Syk by multiple
SH2 domains.
Experimental Procedures
Phosphopeptide binding assays
The preparation of tryptic phosphopeptides from
in vitro autophosphorylated Syk and their separation by
alkaline polyacrylamide gel electrophoresis have been
described in detail.3 In experiments assessing SH2
domain binding activity, proteolysis was terminated by
the addition of 45 mg of soybean trypsin inhibitor. The
collection of tryptic phosphopeptides was applied to 25 ml
of glutathione-Sepharose containing 5 mg of immobilized
GST-SH2 domain and incubated for 90 min at 4 8C. The
resin was washed four times in phosphate-buffered saline
containing 1% (v/v) Triton X-100 and 2 mM dithiothreitol. Bound peptides were recovered by the addition of
20 ml of alkaline PAGE sample buffer.41 Peptides were
separated by 40% alkaline-PAGE and visualized by
autoradiography.3
The peptides DTEVYESPYADPEEIR, DTEVpYESPYADPEEIRDTEVYESPpYADPEEIR, and DTEVpYESPpYADPEEIR were purchased from SynPep. Peptides
contained C-terminal amides and were covalently
coupled to Affi-Gel-10 (BioRad) through the N-terminal
amine. DG75 B cells or Jurkat Tcells (1!107) were lysed in
1 ml of buffer containing 10 mM Hepes (pH 7.5), 150 mM
NaCl, 5 mM EDTA, 1% (v/v) NP-40. Lysates were precleared by incubating with 12.5 ml of the resin without
peptide for 1 h at 4 8C. Unbound proteins were then
adsorbed to 12.5 ml of each peptide-resin at 4 8C for 2 h.
Resins were washed three times with lysis buffer. Bound
proteins were eluted in SDS sample buffer, separated by
1234
SDS-PAGE, transferred to PVDF membranes and analyzed by Western blotting.
Measurement of NFAT activity
Syk-deficient chicken DT40 B cells were generously
provided by Dr T. Kurosaki (Kansai Medical University,
Osaka, Japan). Cells were cultured in RPMI 1640 medium
supplemented with 10% (v/v) heat-inactivated fetal calf
serum, 1% (v/v) chicken serum, 50 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 100 IU/ml of penicillin G, and 100 mg/ml of streptomycin. cDNA for the
expression of site-directed mutants was prepared using
the Transformer mutagenesis kit (Clontech). Cells were
transfected with 15–20 mg of Syk-expression plasmid and
10–15 mg of an NFAT-luciferase reporter construct
(pNFAT Luc (Stratagene)). Cells were activated 24 h
post-transfection with goat anti-chicken IgM (1–2 mg/
ml) or with a combination of PMA (50 ng/ml) and
ionomycin (1.0 mM) for 6 h at 37 8C. Luciferase activity
was determined using the luciferase assay system kit
(Promega). The values reported indicate the activity
produced by anti-IgM-treatment divided by the activity
produced in response to PMA C ionomycin to correct for
differences in transfection efficiency and represent the
average and standard error of three trials. Syk expression
levels were determined by immunoblotting proteins from
cell lysates with the N-19 anti-Syk antibody (Santa Cruz).
NMR sample preparation
The plasmid containing bovine PLCC (residues 663–
759 from PLCg-1) was obtained from the laboratory of
Julie Forman-Kay.24 BL21(DE3) Escherichia coli cells were
used to express PLCC in isotopically enriched minimal
medium at 20 8C. PLCC was initially purified with pTyr
agarose (Sigma), and high molecular mass contaminants
were removed by a Superdex-75 gel-filtration column
(Amersham).
pYpY peptide was obtained in crude form from SynPep.
The sequence of the peptide is DTEVpYESPpYADPE and
contained an N-terminal acetyl group and a C-terminal
amide. The crude peptide was purified using a Pep-RPC
column (Amersham). Fractions containing eluted peptide
were assessed for purity and correct sequence by matrixassisted laser desorption/ionization (MALDI) mass
spectrometry.
Final NMR samples contained 1.5 mM PLCC with a 1:1
molar ratio of protein to peptide in 20 mM Mes (pH 6.0),
100 mM NaCl and 3 mM Tris(2-carboxyethyl)-phosphine
(TCEP). The stoichiometry of the complex was determined from sedimentation velocity ultracentrifugation to
be 1:1. Samples used for X-filtered and 3D 13C-edited
[1H,1H] NOESY experiments were dialyzed against buffer
with 90% (v/v) 2H2O and degassed.
NMR experiments
NMR experiments were performed either on a Varian
INOVA 600 spectrometer equipped with 5 mm [1H, 15N,
13
C] triple-resonance z-axis pulsed-field gradient probes or
a Bruker DRX 500 triple-resonance spectrometer. Sequencespecific assignments of PLCC were made using HNCACB,
CBCA(CO)NH, HNCA, HCCH-TOCSY, C(CO)NH and
HC(CO)NH recorded on uniformly 15N/13C-labeled
PLCC. Aromatic resonances were assigned using 2D
hbCBcgcdHD and hbCBcgcdHDHE experiments. Peptide
assignments were made using 2D X-filtered intrapeptide
Two Phosphotyrosine Requirement of Syk to Bind PLCg
NOESY (tmixZ150 ms) and TOCSY (tmixZ75 ms). Intraprotein proton–proton distance constraints were derived
from 3D 13C-edited [1H,1H] NOESY (tmixZ150 ms) and 3D
15
N-edited [1H,1H] NOESY (tmixZ150 ms). Intercomplex
proton–proton distance constraints were derived from
X-filtered NOESY (tmixZ150 ms).
NMR structure calculations
Cross-peak intensity for the protein–protein NOE
restraints were categorized as strong, medium, weak,
and very weak, and cross-peak intensities from the
X-filtered experiment were uniformly given a range
between 1.8 Å and 6.0 Å. Hydrogen bond restraints
were included for residues 19–28 in aA and residues
77–87 in aB. Helical ranges were identified by the 15NNOE patterns. The phi and psi angles were derived from
TALOS.42
Structures were calculated in two stages using standard
simulated annealing protocols and XPLOR-NIH.43 The
first stage involved PLCC alone with only protein–protein
NMR restraints. Simulated annealing calculations of
PLCC without peptide were performed using 1333
protein–protein NOE-derived restraints, 55 phi and
55 psi torsion angle restraints, and 26 H-bond restraints.
The average structure was calculated from the seven best
PLCC structures defined by lack of NOE violations and
correct main-chain geometry. The average, energyminimized structure of PLCC was used in the second
stage of calculations to dock pYpY to the protein.
Complete assignment of the peptide resonances from
intrapeptide X-filtered NOESY and TOCSY experiments
was not possible because of overlapped peaks. Nonetheless, the two tyrosine residues were uniquely assigned
and 16 intermolecular NOEs from these residues were
used in an initial docking of the peptide to PLCC by
restrained molecular dynamics. This positioning of the
peptide with respect to the SH2 surface allowed assignment of all chemical shift-degenerate intermolecular NOE
interactions.
In the second stage of structure calculations, the
peptide was placed 12 Å from the protein and initial
coordinates were in an extended strand structure. The
peptide was docked to the first-stage structure of PLCC
by restrained molecular dynamics using all 29 intermolecular NOE restraints. The Ca atoms of the protein
were restrained initially, but the side-chain atoms and
peptide were allowed free movement. The long-range
asymptote of the NOE energy term was originally set to
0.01, and the electrostatic energy was excluded. In order
to allow the peptide to move to its proper position, the
van der Waals radii were reduced by a factor of 0.002.
When the peptide reached a distance of approximately
5 Å from the SH2 domain, the NOE energy asymptote
was increased to 1.0, and the Ca atoms were no longer
constrained. Structures of the complex were evaluated at
this point based on NOE violations, overall energy, and
correct geometry. The best-scored structures were refined
using simulated annealing and a force field with full van
der Waals radii and electrostatics. The final structures
were selected based on few NOE violations and correct
geometry.
Surface plasmon resonance
All kinetic and steady state binding experiments were
carried out on a BIAcore 3000 instrument (BIAcore) at
25 8C. A biotin molecule was attached to the N terminus
1235
Two Phosphotyrosine Requirement of Syk to Bind PLCg
of pYpY and pYY by two 6-aminohexanoic acid linkers.
The peptides were immobilized on SA Sensor Chips
(BIAcore). Nanomolar concentrations of peptide were
immobilized, and remaining streptavidin sites were
blocked with free biotin. A reference flow-cell was treated
by the same procedure without immobilization of the
peptide.
Kinetic experiments were performed at 50 ml/min or
80 ml/min with 1 min injections of SH2 domain.
Dissociation was allowed to occur for 3 min, and then
the chip was regenerated with 0.05% (w/v) SDS. Kinetic
constants for association, ka, and dissociation, kd, were
calculated by BIAevaluation 3.2 software.
Steady-state experiments were performed at 15 ml/min
with 1 min injections of PLCC. Dissociation and regeneration was as described above. The following equation was
fit with Origin software to determine the equilibrium
dissociation constant, KD, of the complex:
3.
4.
5.
RU Z ðKD ÞðRmax Þ=ðKD C ConcÞ
where RU is the relative response, Rmax is the maximum
response and Conc is the concentration of PLCC. Binding
curves are provided as Supplementary Data.
6.
Chemical-shift perturbations
15
N-labeled PLCC was prepared as described above.
Purified protein was resuspended in 100 mM sodium
phosphate (pH 6.5) with 3 mM DTT and 10% (v/v) 2H2O.
Spectra were taken with increasing amounts of peptide
with peptide to protein molar ratios of 0:1, 0.3:1, 0.6:1 and
1.1:1. Peaks were assigned based on the assignments for
pYpY bound to PLCC.
7.
8.
9.
Acknowledgements
We thank Dr John Burgner for useful discussions
and assisting with BIAcore experiments. We thank
Chris Isaacson for assisting with the GST pulldown
experiments. This work was supported by National
Institutes of Health (NIH) grants GM39478 (to
C.B.P.) and CA37372 (to R.L.G.), a Purdue University reinvestment grant, and a grant to the Purdue
Cancer Center (CA23568). T.D.G. was supported by
a Purdue Research Foundation Fellowship and by
NIH Biophysics Training Grant GM008296.
10.
11.
12.
Supplementary Data
Supplementary data associated with this article
can be found, in the online version, at doi:10.1016/
j.jmb.2005.11.095
References
1. Hutchcroft, J. E., Harrison, M. L. & Geahlen, R. L.
(1992). Association of the 72-kDa protein-tyrosine
kinase Ptk72 with the B-cell antigen receptor. J. Biol.
Chem. 267, 8613–8619.
2. Yamada, T., Taniguchi, T., Yang, C., Yasue, S., Saito, H.
& Yamamura, H. (1993). Association with B-cell-
13.
14.
15.
antigen receptor with protein-tyrosine kinaseP72(Syk) and activation by engagement of membrane
Igm. Eur. J. Biochem. 213, 455–459.
Keshvara, L. M., Isaacson, C. C., Yankee, T. M.,
Sarac, R., Harrison, M. L. & Geahlen, R. L. (1998). Sykand Lyn-dependent phosphorylation of Syk on
multiple tyrosines following B cell activation includes
a site that negatively regulates signaling. J. Immunol.
161, 5276–5283.
Chan, T. C. K., Chang, C. J., Koonchanok, N. M. &
Geahlen, R. L. (1993). Selective-inhibition of the
growth of Ras-transformed human bronchial epithelial-cells by emodin, a protein-tyrosine kinase
inhibitor. Biochem. Biophy. Res. Commun. 193,
1152–1158.
Neumeister, E. N., Zhu, Y. X., Richard, S., Terhorst, C.,
Chan, A. C. & Shaw, A. S. (1995). Binding of Zap-70 to
phosphorylated T-cell receptor-Zeta and receptor-Eta
enhances its autophosphorylation and generates
specific binding-sites for Sh2 domain-containing
proteins. Mol. Cell. Biol. 15, 3171–3178.
Lupher, M. L., Rao, N., Lill, N. L., Andoniou, C. E.,
Miyake, S., Clark, E. A. et al. (1998). Cbl-mediated
negative regulation of the Syk tyrosine kinase—a
critical role for Cbl phosphotyrosine-binding domain
binding to Syk phosphotyrosine 323. J. Biol. Chem. 273,
35273–35281.
Rao, N., Lupher, M. L., Ota, S., Reedquist, K. A.,
Druker, B. J. & Band, H. (2000). The linker
phosphorylation site Tyr(292) mediates the negative
regulatory effect of Cbl on ZAP-70 in T cells.
J. Immunol. 164, 4616–4626.
Sohn, H. W., Gu, H. & Pierce, S. K. (2003). Cbl-b
negatively regulates B cell antigen receptor signaling
in mature B cells through ubiquitination of the
tyrosine kinase Syk. J. Expt. Med. 197, 1511–1524.
Magnan, A., Di Bartolo, V., Mura, A. M., Boyer, C.,
Richelme, M., Lin, Y. L. et al. (2001). T cell development
and T cell responses in mice with mutations affecting
tyrosines 292 or 315 of the ZAP-70 protein tyrosine
kinase. J. Expt. Med. 194, 491–505.
Gong, Q., Jin, X. H., Akk, A. M., Foger, N., White, M.,
Gong, Q. Q. et al. (2001). Requirement for tyrosine
residues 315 and 319 within zeta chain-associated
protein 70 for T cell development. J. Expt. Med. 194,
507–518.
Simon, M., Vanes, L., Geahlen, R. L. & Tybulewicz,
V. L. J. (2005). Distinct roles for the linker region
tyrosines of Syk in Fc epsilon RI signaling in primary
mast cells. J. Biol. Chem. 280, 4510–4517.
Hong, J. J., Yankee, T. M., Harrison, M. L. & Geahlen, R. L.
(2002). Regulation of signaling in B cells through the
phosphorylation of Syk on linker region tyrosines—a
mechanism for negative signaling by the Lyn tyrosine
kinase. J. Biol. Chem. 277, 31703–31714.
Law, C. L., Chandran, K. A., Sidorenko, S. P. &
Clark, E. A. (1996). Phospholipase C-gamma 1
interacts with conserved phosphotyrosyl residues
in the linker region of Syk and is a substrate for Syk.
Mol. Cell. Biol. 16, 1305–1315.
Deckert, M., Tartare-Deckert, S., Couture, C.,
Mustelin, T. & Altman, A. (1996). Functional and
physical interactions of Syk family kinases with the
Vav proto-oncogene product. Immunity, 5, 591–604.
Zhang, J., Berenstein, E. & Siraganian, R. P. (2002).
Phosphorylation of Tyr342 in the linker region of Syk
is critical for Fc epsilon RI signaling in mast cells. Mol.
Cell. Biol. 22, 8144–8154.
1236
Two Phosphotyrosine Requirement of Syk to Bind PLCg
16. Wu, J., Zhao, Q. H., Kurosaki, T. & Weiss, A. (1997).
The Vav binding site (Y315) in ZAP-70 is critical for
antigen receptor-mediated signal transduction.
J. Expt. Med. 185, 1877–1882.
17. Williams, B. L., Irvin, B. J., Sutor, S. L., Chini, C. C. S.,
Yacyshyn, E., Wardenburg, J. B. et al. (1999). Phosphorylation of Tyr319 in ZAP-70 is required for T-cell
antigen receptor-dependent phospholipase C-gamma
1 and Ras activation. EMBO J. 18, 1832–1844.
18. Pelosi, M., Di Bartolo, V., Mounier, V., Mege, D.,
Pascussi, J. M., Dufour, E. et al. (1999). Tyrosine 319 in
the interdomain B of ZAP-70 is a binding site for the
Src homology 2 domain of Lck. J. Biol. Chem. 274,
14229–14237.
19. Brdicka, T., Kadlecek, T. A., Roose, J. P., Pastuszak, A. W.
& Weiss, A. (2005). Intramolecular regulatory switch in
ZAP-70: analogy with receptor tyrosine kinases. Mol.
Cell. Biol. 25, 4924–4933.
20. Wybenga-Groot, L. E., Baskin, B., Ong, S. H., Tong, J.,
Pawson, T. & Sicheri, F. (2001). Structural basis for
autoinhibition of the EphB2 receptor tyrosine kinase
by the unphosphorylated juxtamembrane region. Cell
(Cambridge, MA), 106, 745–757.
21. Bradshaw, J. M., Mitaxov, V. & Waksman, G. (1999).
Investigation of phosphotyrosine recognition by the
SH2 domain of the Src kinase. J. Mol. Biol. 293, 971–985.
22. Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G.,
Pawson, T., Haser, W. G. et al. (1993). Sh2 domains
recognize specific phosphopeptide sequences. Cell, 72,
767–778.
23. Sheinerman, F. B., Al-Lazikani, B. & Honig, B. (2003).
Sequence, structure and energetic determinants of
phosphopeptide selectivity of SH2 domains. J. Mol.
Biol. 334, 823–841.
24. Pascal, S. M., Singer, A. U., Gish, G., Yamazaki, T.,
Shoelson, S. E., Pawson, T. et al. (1994). Nuclearmagnetic-resonance structure of an Sh2 domain of
phospholipase C-gamma-1 complexed with a highaffinity binding peptide. Cell, 77, 461–472.
25. Carpenter, G. & Ji, Q. S. (1999). Phospholipase
C-gamma as a signal-transducing element. Expt. Cell
Res. 253, 15–24.
26. Vines, C. M., Potter, J. W., Xu, Y., Geahlen, R. L., Costello,
P. S., Tybulewicz, V. L. et al. (2001). Inhibition of beta 2
integrin receptor and Syk kinase signaling in monocytes
by the Src family kinase Fgr. Immunity, 15, 507–519.
27. Moon, K. D., Post, C. B., Dirdem, D. L., Zhou, Q.,
De, P., Harrison, M. L. & Geahlen, R. L. (2005).
Molecular basis for a direct interaction between the
Syk protein-tyrosine kinase and phosphoinositide
3-kinase. J. Biol. Chem. 280, 1543–1551.
28. Eck, M. J., Atwell, S. K., Shoelson, S. E. & Harrison, S. C.
(1994). Structure of the regulatory domains of the
Src-family tyrosine kinase Lck. Nature, 368, 764–769.
29. Eck, M. J., Shoelson, S. E. & Harrison, S. C. (1993).
Recognition of a high-affinity phosphotyrosyl peptide
by the Src homology-2 domain of P56(Lck). Nature, 362,
87–91.
30. Hu, J. J., Liu, J., Ghirlando, R., Saltiel, A. R. &
Hubbard, S. R. (2003). Structural basis for recruitment
of the adaptor protein APS to the activated insulin
receptor. Mol. Cell. 12, 1379–1389.
31. Kay, L. E., Muhandiram, D. R., Wolf, G., Shoelson, S. E.
& Forman-Kay, J. D. (1998). Correlation between
binding and dynamics at SH2 domain interfaces.
Nature Struct. Biol. 5, 156–163.
32. Nioche, P., Liu, W. Q., Broutin, I., Charbonnier, F.,
Latreille, M. T., Vidal, M. et al. (2002). Crystal
structures of the SH2 domain of Grb2: highlight on
the binding of a new high-affinity inhibitor. J. Mol.
Biol. 315, 1167–1177.
33. Waksman, G., Kominos, D., Robertson, S. C., Pant, N.,
Baltimore, D., Birge, R. B. et al. (1993). Crystal structure
of the phosphotyrosine recognition domain Sh2 of V-Src
complexed with tyrosine phosphorylated peptides.
Nature, 358, 646–653.
34. Hwang, P. M., Li, C. J., Morra, M., Lillywhite, J.,
Muhandiram, D. R., Gertler, F. et al. (2002). A ‘threepronged’ binding mechanism for the SAP/SH2D1A
SH2 domain: structural basis and relevance to the
XLP syndrome. EMBO J. 21, 314–323.
35. Breeze, A. L., Kara, B. V., Barratt, D. G., Anderson, M.,
Smith, J. C., Luke, R. W. et al. (1996). Structure of a
specific peptide complex of the carboxy-terminal SH2
domain from the p85 alpha subunit of phosphatidylinositol 3-kinase. EMBO J. 15, 3579–3589.
36. Siegal, G., Davis, B., Kristensen, S. M., Sankar, A.,
Linacre, J., Stein, R. C. et al. (1998). Solution structure
of the C-terminal SH2 domain of the p85 alpha
regulatory subunit of phosphoinositide 3-kinase.
J.M. Biol. 276, 461–478.
37. Weber, T., Schaffhausen, B., Liu, Y. X. & Gunther, U. L.
(2000). NMR structure of the N-SH2 of the p85 subunit
of phosphoinositide 3-kinase complexed to a doubly
phosphorylated peptide reveals a second phosphotyrosine binding site. Biochemistry, 39, 15860–15869.
38. Mallis, R. J., Brazin, K. N., Fulton, D. B. &
Andreotti, A. H. (2002). Structural characterization
of a proline-driven conformational switch within
the Itk SH2 domain. Nature Struct. Biol. 9,
900–905.
39. Salomon, A. R., Ficarro, S. B., Brill, L. M., Brinker, A.,
Phung, Q. T., Ericson, C. et al. (2003). Profiling of
tyrosine phosphorylation pathways in human cells
using mass spectrometry. Proc. Natl Acad. Sci. USA,
100, 443–448.
40. Lubman, O. Y. & Waksman, G. (2003). Structural and
thermodynamic basis for the interaction of the Src
SH2 domain with the activated form of the PDGF
beta-receptor. J. Mol. Biol. 328, 655–668.
41. West, M. H. P., Wu, R. S. & Bonner, W. M. (1984).
Polyacrylamide-gel electrophoresis of small peptides.
Electrophoresis, 5, 133–138.
42. Cornilescu, G., Delaglio, F. & Bax, A. (1999). Protein
backbone angle restraints from searching a database
for chemical shift and sequence homology. J. Biomol.
NMR, 13, 289–302.
43. Schwieters, C. D., Kuszewski, J. J., Tjandra, N. &
Clore, G. M. (2003). The XPLOR-NIH NMR molecular
structure determination package. J. Magn. Reson. 160,
66–74.
Edited by M. F. Summers
(Received 22 September 2005; received in revised form 30 November 2005; accepted 30 November 2005)
Available online 27 December 2005